PACTRIMS

Association of Sri Lankan Neurologists

European Charcot Foundation

GUTHY JACKSON charitable Foundation

Indian Academy of Neurology

Hong Kong Multiple Sclerosis Society

Sclerosis Society International Foderation

日本神経免疫学会   名誉会員、国際対応委員会、理事・監事選任委員会  

2013年 - 現在   

Association of Sri Lankan Neurologists   Honorary Member  

2012年 - 現在   

日本神経治療学会   特別補佐国際化担当、国際化委員会、会則あり方委員会  

2012年 - 現在   

PACTRIMS   President(Executive Committee Member)  

2007年 - 現在   

日本神経感染症学会   評議員  

2005年 - 2022年   

日本神経学会   多発性硬化症／視神経脊髄炎診療ガイドライン作成委員会  

1999年 - 現在   

Humanized-aquaporin-4-expressing rat created by gene-editing technology and its use to clarify the pathology of neuromyelitis optica spectrum disorder.

Namatame C, Abe Y, Miyasaka Y, Takai Y, Matsumoto Y, Takahashi T, Mashimo T, Misu T, Fujihara K, Yasui M, Aoki M

Int J Mol Sci   25 ( 15 )   8169   2024年7月

Neuromyelitis optica spectrum disorders registry system in Iran: Validity of data sets.

Khodaie F, Mohamadi M, Ebrahimi Y, Sahraian MA, Moghadasi AN, Ayoubi S, Goudarzi H, Paybast S, Kamyari N, Asgari N, Fujihara K, Heidari H, Eskandarieh S

Mult Scler Relat Disord   87   105685   2024年7月

Safety and efficacy of inebilizumab in patients with neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.

Cree AC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL, on behalf of the N-MOmentum study investigators.

Lancet Neurol   23 ( 6 )   588 - 602   2024年6月

Stochastic models for the development and disease course of multiple sclerosis.

Akaishi T, Misu T, Takahashi T, Fujihara K, Fujimori J, Nakashima I, Aoki M

Clin Neurol Neurosurg   239   108224   2024年4月

Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.

Nakashima I, Nakahara J, Yasunaga H, Yamashita M, Nishijima N, Satomura A, Nio M, Fujihara K

Mult Scler Relat Disord   84   105502   2024年4月

Dynamic changes in patient admission and their disabilities in multiple sclerosis and neuromyelitis optica: a Japanese nationwide administrative data study.

Matsumoto Y, Tarasawa K, Misu T, Namatame C, Takai Y, Kuroda K, Fujihara K, Fushimi K, Fujimori K, Aoki M.

Mult Scler Relat Disord   81   105349   2024年1月

Differential diagnosis of suspected multiple sclerosis: global health considerations.

Correale J, Solomon AJ, Cohen JA, Banwell BL, Gracia F, Gyang TV, de Bedoya FHD, Harnegie MP, Hemmer B, Jacob A, Kim HJ, Marrie RA, Mateen FJ, Newsome SD, Pandit L, Prayoonwiwat N, Sahraian MA, Sato DK, Saylor D, Shi FD, Siva A, Tan K, Viswanathan S, Wattjes M, Weinshenker B, Yamout B, Fujihara K

Lancet Neurol   23 ( 10 )   1035 - 1049   2024年1月

Myelin oligodendrocyte glycoprotein antibody-associated disorders: an overview.

Misu T, Matsumoto Y, Kaneko K, Takahashi T, Takai Y, Ono H, Namatame C, Nishiyama S, Fujimori J, Kuroda H, Nakashima I, Fujihara K, Aoki M.

Clin Exp Neuroimmunol.   2023年12月

Microfibrillar-associated protein 4 as potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: pathological and clinical aspects.

Samadzadeh S, Olesen MN, Wirenfeldt M, Möller S, Misu T, Soelberg K, Frederiksen JL, Heegaard S, Mariotto S, Fujihara K, Ruprecht K, Andersen TL, Marignier R, Lillevang ST, Flanagan EP, Pittock SJ, Kim HJ, Bennett JL, Friedeman Paul F, Sorensen GL, Weinshenker BG, Lassmann H, Asgari N.

Mult Scler.   29 ( 14 )   1721 - 1735   2023年10月

Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.

Matsumoto Y, Kaneko K, Takahashi T, Takai Y, Namatame C, Kuroda H, Misu T, Fujihara K, Aoki M.

Brain.   146 ( 9 )   3938 - 3948   2023年9月

Epidemiology of MOGAD: A review of prevalence and incidence worldwide.

Hor JY, Fujihara K.

Front Neurol.   15 ( 14 )   1260358   2023年9月

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.

Aktas O, Hartung HP, Smith MA, Rees WA, Fujihara K, Paul F, Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Cutter G, She D, Gunsior M, Cimbora D, Katz E, Cree BAC, N-MOmentum study investigators.

J Neurol Neurosurg Psychiatry.   94 ( 9 )   757 - 768   2023年9月

Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.

Fujihara K, Kim HJ, Saida T, Misu T, Nagano Y, Totsuka N, Iizuka M, Kido S, Terata R, Okumura K, Hirota S, Cree BAC.

Mult Scler Relat Disord.   79   104938   2023年8月

Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.

Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W, Waubant EL, Yamout B, Cohen JA.

Lancet Neurol.   22 ( 8 )   750 - 768   2023年8月

Associations between neuromyelitis optica spectrum disorder, Sjogren's ¨ syndrome, and conditions with electrolyte disturbances.

Akaishi T, Tarasawa K, Matsumoto Y, Sandhya P, Misu T, Fushimie K, Takahashi T, Fujimori J, Ishii T, Fujimori K, Yaegashi N, Nakashima I, Fujihara K, Aoki M.

J Neurol Sci.   452   120742   2023年7月

Time-Dependent Analysis of Sicca Symptoms and Anti-Ro/SSA and Anti-La/SSB Antibodies in Patients with AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.

Akaishi T, Takahashi T, Misu T, Fujihara K, Nakashima I, Aoki M.

Tohoku J Exp Med.   260 ( 3 )   215 - 221   2023年7月

Pathology of MOGAD: a comparison with MS and AQP4 antibody-positive NMOSD.

Takai Y, Misu T, Fujihara K, Aoki M.

Front Neurol.   21 ( 14 )   1209749   2023年7月

Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method.

Gold R, Barnett M, Chan A, Feng H, Fujihara K, Giovannoni G, Motalban X, Shi FD, Tintore M, Xue Q, Yang C, Zhou H.

Ther Adv Neurol Disord.   14 ( 16 )   2023年7月

Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan.

Nakashima I, Nakahara J, Yokote H, Manabe Y, Okamura K, Hasegawa K, Fujihara K.

Ther Adv Neurol Disord.   16   2023年6月

Attack adjudication in neuromyelitis optica spectrum disorder: substantiation of criteria by magnetic resonance imaging and biomarkers in N-Momentum.

Weinshenker BG, Wingerchuk DM, Green AJ, Bennett JL, Kim HJ, Pittock SJ, Fujihara K, Paul F, Cutter G, Marignier R, Aktas O, Hartung HP, She D, Smith M, Rees W, Patterson K, Cimbora D, Katz E, Cree BAC, N-MOmentum study investigator.

Mult Scler.   29 ( 8 )   945 - 955   2023年6月

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.

Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De Seze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto MA, Law L, Leite IS, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK, Vaknin-Dembinsky A.

Neurol Neuroimmunol Neuroinflamm.   10 ( 4 )   e200124 - e200124   2023年5月

White blood cell count profiles in the acute phase of AQP4-IgG seropositive NMOSD and MOG-IgG-associated disease.

Akaishi T, Misu T, Fujihara K, Nakaya K, Nakaya N, Nakamura T, Kogure M, Hatanaka R, Itabashi F, Kanno I, Kaneko K, Takahashi T, Fujimori J, Takai Y, Nishiyama S, Ishii T, Aoki M, Nakashima I, Hozawa A.

Sci Rep.   13 ( 1 )   6481 - 6481   2023年4月

Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): International MOGAD Panel Proposed Criteria.

Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan E, Ramanathan S, Waters P, Tenembaum S, MD, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock S, Fujihara K, Palace J.

Lancet Neurol.   22 ( 3 )   268 - 282   2023年3月

SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.

Bennett JL, Fujihara K, Kim HJ, Marignier R, O’Connor KC, Sergott RC, Traboulsee A, Wiendl H, Wuerfel J, Zamvil SS, Anania VG, Buffels R, Künzel T, Lekkerkerker AN, Lennon-Chrimes S, Pittock SJ.

Front Neurol.   17 ( 14 )   1114667   2023年2月

Contrast-enhanced double inversion recovery sequence for patients with multiple sclerosis: feasibility of subtraction images between pre- and post-contrast images.

Tomura N, Saginoya T, Sanpei T, Konno T, Fujihara K.

Acta Radiol   64 ( 2 )   719 - 724   2023年2月

A novel association of osmotic demyelination in Sjogren’s syndrome ¨ prompts revisiting role of aquaporins in CNS demyelinating diseases: A literature review.

Sandhya P, Akaishi T, Fujihara K, Aoki M.

Mult Scler Relat Disord.   69   104466   2023年1月

Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.

Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, von Büdingen HC, Klingelschmitt G, Stokmaier D, Bennett JL.

Neurol Neuroimmunol Neuroinflamm.   10 ( 1 )   e200071   2022年12月

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.

Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimbora D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC on behalf of the N-MOmentum study investigators.

EBioMedicine.   86   104321   2022年12月

Diagnosis and classification of optic neuritis.

Petzold A, Fraser C, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov M, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi P, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, DeSeze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Froment Tilikete C, Fujihara K, Gálvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Hernández Martínez de Lapiscina E, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagrèze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Muñoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, Rebolleda G, Reddel S, Rejdak K, Rejdak R, Rodriguez-Morales A, Rougier MB, Sa MJ, Sanchez-Dalmau B, Saylor D, Shatriah I, Siva A, Stiebel-Kalish H, Szatmary G, Ta L, Tenembaum S, Tran H, Trufanov Y, Van Pesch V, Wang AG, Wattjes M, Willoughby E, Zakaria M, Zvornicanin J, Balcer L, Plant GT.

Lancet Neurol.   21 ( 12 )   1120 - 1134   2022年12月

Neuromyelitis Optica Spectrum Disorders in Africa (A Narrative Review of 622 Cases).

Kissani N, Ouadika1 RJB, Kishk NA, Chaymae O, Ibrahim EAA, Maiga Y, Paul R, Daniel GM, Hamid A, Assogba K, Gaye NM, Hor JY, Tegueu CK, Marignier R, Palace J, Weinshenker BG, Ragab AH, Fujiharaa K. Neuromyelitis Optica Spectrum Disorders in Africa (A Narrative Review of 622 Cases).

Open Access Library J.   e9649   2022年9月

Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.

Akaishi T, Misu T, Fujihara K, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, aoki M, Nakashima I.

J Neurol.   269 ( 6 )   3136 - 3146   2022年6月

Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: a case series.

Yamamura T, Araki M, Fujihara K, Okuno T, Misu T, Guo YC, Hemingway C, Matsushima J, Sugaya N, Yamashita M, von Büdingen HC, Miyamoto K.

Mult Scler Relat Disord.   61   103772   2022年5月

Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.

Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, Nakashima I, Tanvir I, Paul F, Pittock SJ.

Neurol Ther.   11 ( 1 )   123 - 135   2022年5月

RGMa signal in macrophages induces neutrophil-related astrocytopathy in NMO.

4. Iwamoto S, Itokazu T, Sasaki A, Kataoka H, Tanaka S, Hirata T, Miwa K, Suenaga T, Takai Y, Misu T, Fujihara K, Yamashita T.

Ann Neurol.   91 ( 4 )   532 - 547   2022年4月

Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.

Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, Nakashima I, Tanvir I, Paul F, Pittock SJ.

Neurol Ther.   11 ( 1 )   123 - 135   2022年3月

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.

Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Róisín Armstrong R, Wingerchuk DM, and the PREVENT Study Group.

Mult Scler.   28 ( 3 )   480 - 486   2022年3月

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.

Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Róisín Armstrong R, Wingerchuk DM, and the PREVENT Study Group.

Mult Scler.   28 ( 3 )   480 - 486   2022年3月

AQP4-IgG seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.

1. Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, Wingerchuk D, Green AJ, Fujihara K, Cutterj G, Aktas O, Hartung HP, Drappa J, Ratchford JN, She D, Smith M, Rees W, Cimbora D, Katz E, Cree BAC, on behalf of the N-MOmentum study investigators.

Mult Scler Relat Disord   57   103356   2022年1月

Difference of anti-viral immunity induced by two mRNA vaccines: Implications in MS patients treated with anti-CD20-depleting therapy.

Tanaka M, Fujihara K.

Clin Exp Neuroimmunol   ( 13 )   5 - 6   2022年

Autoantibodies in central nervous system and neuromuscular autoimmune disorders A narrative review.

Joen MY, Seok JM, Fujihara K, Kim BJ.

Precis Future Med.   6 ( 2 )   105 - 116   2022年

Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.

Akaishi T, Misu T, Fujihara K, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, aoki M, Nakashima I.

J Neurol.   2021年11月

White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments.

Akaishi T. Misu T, Fujihara K. Nakaya N, Nakamura T, Kogure M, Hatanaka R, Itabashi F, Kanno I, Takahashi T, Kuroda H, Fujimori J, Takai Y, Nishiayama S, Kaneko K, Ishii T, Aoki M, Nakashima I, Hozawa A.

Sci Rep.   11 ( 1 )   22357   2021年11月

GRP78 antibodies are associated with blood-brain barrier-breakdown in anti-myelin oligodendrocyte glycoprotein antibody-associated disorder.

Shimizu F, Ogawa R, Mizukami Y, Watanabe K, Hara K, Kadono C, Takahashi T, Misu T, Takeshita Y, Sano Y, Fujisawa M, Maeda T, Nakashima I, Fujihara K, Kanda T.

Neurol Neuroimmunol Neuroinflamm.   9 ( 1 )   e1038   2021年11月

Patient-reported burden of symptoms in neuromyelitis optica: a secondary analysis on pain and quality of life.

Fujihara K, Hattori S, Kleiter I, Levy M, Matsuda Y, Mitsutake A, Haramura M, Palace J, Yamamura T. on behalf of The Guthy-Jackson Charitable Foundation NMOSD Quality of Life Working Group.

J Neurol Sci.   428   117546   2021年9月

MOG-antibody associated disease.

Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Dphil HA, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, De Sèze J, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selmaj K, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, Hemmer B.

Lancet Neurol.   20 ( 9 )   762 - 772   2021年9月

Five-year visual outcome after optic neuritis in anti-MOG antibody-associated disease.

Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I.

Mult Scler Relat Disord Mult Scler Relat Disord.   56   103222   2021年8月

Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.

Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, EKatz E, Cree BAC.

Neurol Neuroimmunol Neuroinflamm.   8 ( 3 )   e978   2021年5月

Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.

Takai Y, Misu T, Suzuki H, Takahashi T, Okada H, Tanaka S, Okita K, Sasou S, Watanabe M, Namatame C, Matsumoto Y, Ono H, Kaneko K, Nishiyama S, Kuroda H, Nakashima I, Lassmann H, Fujihara K, Itoyama Y, Aoki M.

Brain.   144 ( 8 )   2401 - 2415   2021年5月

Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder.

Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S, Ogawa R, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakashima I.

Neurology.   97 ( 1 )   e1 - e12   2021年5月

Acute retrobulbar optic neuritis with anti-myelin oligodendrocyte glycoprotein antibody-associated disease complicated with microscopic polyangiitis: a case report.

Asano T, Saito Y, Matsuoka N, Temmoku J, Fujita Y, Hattori K, Kobayashi S, Ojima A, Takahashi T, Matsumoto H, Yashiro-Furuya M, Sato S, Kobayashi H, Watanabe H, Yano K, Sasajima T, Fujihara K, Migita K.

Medicine (Baltimore).   100 ( 15 )   e24889   2021年4月

Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.

Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, Yountz M, Wingerchuk DM, Pittock SJ, Levy M, Berthele A, Totolyan N, Palace J, Barnett MH, Fujihara K; PREVENT Study Group.

Mult Scler Relat Disord.   50 ( 102849 )   2021年2月

Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.

Akaishi T, Himori N, Takeshita T, Fujihara K, Misu T, Takahashi T, Fujimori J, Ishii T, Aoki M, Nakazawa T, Nakashima I.

Brain Behav.   11 ( 5 )   e02083   2021年2月

Long-term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.

Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, MD, Pittock, SJ, for the PREVENT Study Group.

Ann Neurol.   89 ( 6 )   1088 - 1098   2021年2月

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.

Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E.

Mult Scler.   27 ( 13 )   2052 - 2061   2021年2月

Progression pattern of neurological disability in reference to clinical attacks in anti-MOG antibody-associated disorders.

Akaish T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishi T, Aoki M, Fujihara K, Nakashima I.

J Neuroimmunol   31 ( 351 )   577467   2021年2月

Early Treatment Initiation with Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder.

Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Abe M, Ishii T, Aoki M, Nakashima I.

Front Neurol   22 ( 12 )   608149   2021年2月

Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.

Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M, Ishii T, Aoki M, Nakashima I.

J Neurol   2021年1月

CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder.

Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, Fujihara K, Aoki M.

Heliyon   7 ( 1 )   e05899 - e05899   2021年1月

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial.

Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S, on behalf of the PREVENT Study Group.

Mult Scler Relat Disord   ( 47 )   102641   2021年1月

Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.

Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, Nishiyama S, Fujihara K, Aoki M.

Mult Scler Relat Disord   22 ( 49 )   102750   2021年1月

New therapies for neuromyelitis optica spectrum disorders.

Levy M, Fujihara K. Place J.

Lancet Neurol.   20 ( 1 )   60 - 67   2021年1月

Patterns of cortical grey matter thickness reduction in multiple sclerosis.

Fujimori, Fujihara K, Wattjes M, Nakashima I.

Brain Behav   27   e02050   2021年1月

Distinctive lesions of bran MRI between MOG-antibody-associated and AQP4-antibody-associated diseases.

Matsumoto Y, Misu T, Mugikura S, Takai Y, Nishiyama S, Kuroda H, Takahashi T, Fujimori J, Nakashima I, Fujihara K, Aoki M.

J Neurol Neurosurg Psychiatry   92 ( 6 )   2020年12月

Treatment of MOG Antibody Associated Disorders: Results of an International Survey.

Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintz en RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana-Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, Lim M, Huda S, Jacob A.

J Neurol   267 ( 12 )   3565 - 3577   2020年12月

Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody.

Akaishi T, Fujimori J, Takahashi T, Misu T, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M, Ishii T, Aoki M, Fujihara K, Nakashima I.

J Neuroimmunol   15 ( 349 )   577431   2020年12月

Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD.

Akaishi T, Takshita T, Himori N, Takahashi T, Misu T, Ogawa R, Kaneko K, Fujimori J, Abe M, Ishii T, Fujihara K, Aoki M, Nakazawa T, Nakashima I.

Front Neurol   2 ( 11 )   932   2020年9月

Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.

Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D; Mughal T, Yamamura T.

Neurol Neuroimmunol Neuroinflamm   20 ( 7(5) )   e841   2020年8月

Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders.

Akaishi T、Takahashi T, Misu T, Abe M, Ishii T, Fujimori J, Aoki M, Fujihara K, Nakashima I.

Sci Rep   17 ( 10(1) )   13890   2020年8月

Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis.

Akaishi T, Takahashi T, Fujihara K, Misu T, Nishiyama S, Takai Y, Fujimori J, Abe M, Ishii T, Aoki M, Nakashima I.

Mult Scler Relat Disord   7 ( 45 )   102382   2020年7月

Measurements of corpus callosum index and fractional anisotropy of the corpus callosum with their cutoffs are useful to comprehend global brain volume loss in multiple sclerosis.

Fujimori J, MD, Uryu K, Fujihara K, Wattjes MP, Suzuki C, Nakashima I.

Mult Scler Relat Disord   8 ( 45 )   102388   2020年7月

Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide.

Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, Pittock SJ, Palace J, Wingerchuk DM, Behne JM, Yeaman MR, Fujihara K, with the Guthy-Jackson Charitable Foundation International Clinical Consortium for NMOSD.

Front Neurol   26 ( 11 )   501   2020年6月

Risk factors of attacks in neuromyelitis optica spectrum disorders.

Akaishi T, Takahashi T, Fujihara K, Misu T, Abe M, Ishii T, Aoki M, Nakashima I.

J Neuroimmunol   15 ( 343 )   577236   2020年6月

Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients.

Whittam DH, Cobo-Calvo A, Chiriboga ASL, Pardo S, Gornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, Capobianco M, Gibbons E, Karthikeayan V, Brochet B, Audoin R, Mathey G, Laplaud D, Thouvenot F, Cohen M, Tourbah A, Maillart E, Ciron J, Deschamps R, Biotti D, Rostasy K, Neuteboom R, Hemingway C, Forsyth R, Matiello M, Webb S, Hunt D, Murray K, Hacohen Y, Lim M, Leite MI, Palace J, Solomon T, Lutterotti A, Fujihara K, Nakashima I, Bennett J, Pandit L, Chitnis T, Weinshenker BG, Wildemann B, Sato DK, Kim SH, Huda S, Kim HJ, Reindl M, Levy M, Jarius S, Tenembaum S, Paul F, Pittock S, Marignier R, Anu Jacob A.

Mult Scler Relat Disord   2 ( 44 )   102251   2020年6月

Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.

Fujihara K. Cook L.

Curr Opin Neurol   33 ( 3 )   300 - 308   2020年6月

Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes.

Tsymala I, Nigritinou M, Zeka B, Schulz R, Niederschick F, Matković M, Bauer IJ, Szalay M, Schanda K, Lerch M, Misu T, Fujihara K, Bennett JL, Dahle C, Pache F, Rommer P, Leutmezer F, Illes Z, Leite MI, Palace J, Scholze P, Reindl M, Lassmann H, Bradl M.

Acta Neuropathol Commun   15 ( 8(1) )   49   2020年4月

Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis.

Akaishi T, Takahashi T, Fujihara K, Abe M, Ishii T, Aoki M, Nakashima I, Misu T, Mugikura S.

PLoS One   3 ( 15(4) )   e0231225   2020年4月

MOG-IgG-associated disease.

Kaneko K, Takahahi T, Misu T, Nakashima I, Fujihara K.

Clin Exp Neuroimmunol   11 ( Suppl. 1 )   28 - 33   2020年

Perivenous demyelination:association with anti-myelin oligodendrocyte glycoprotein.

Misu T, Takai Y, Takahashi T, Nakashima I, Fujihara K, Aoki M.

Clin Exp Neuroimmunol   11 ( Suppl. 1 )   22 - 27   2020年

Trila of satralizumab in neuromyelitis optica spectrum disorder

Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J

N Engl J   2019年11月

Long-term outcome of a group of Japanese children with myelin-oligodendrocyte glycoprotein encephalomyelitis without preventive immunosuppressive therapy

Hino-Fukuyo N, Haginoya K, Takahashi T, Nakashima I, Fujihara K, Takai Y, Akasaka M, Kure S

Brain Dev   2019年10月

Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behçet’s disease.

Fujimori J, Takahashi T, Matsumoto Y, Fujihara K, Takai Y, Misu T, Nakashima I

J Neuroimmunol   2019年6月

Neuromyelitis optica spectrum disorders: still evolving and broadening

Fujihara K

Curr Opin Neurol   2019年6月

【補体標的治療の現状と展望】視神経脊髄炎

黒田　宙、藤原　一男

BRAIN and NERVE:　神経研究の進歩   71 ( 6 )   573 - 580   2019年6月

治療法の再整理とアップデートのために　専門家による私の治療　急性散在脳脊髄炎（ADEM）

松本勇貴, 藤原一男

日本医事新報   ( 4964 )   42 - 42   2019年6月

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders: tools for clinical practice and drug trial design

Palace J, Lin DY, Zeng D, Majed M, Elsone L, Hamid S, Messina S, Misu T, Sagen J, Whittam D, Takai Y, Leite MI, Weinshenker B, Cabre P, Jacob A, Nakashima I, Fujihara K, Pittock SJ

Brain   2019年5月

Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat.

Hillebrand S, Schanda K, Nigritinou M, Tsymala I, Böhm D, PeschL P, Bauer J, Takai T, Fujihara K, Nakashima I, Misu T, Reindl M, Lassmann H, Bradl M.

Acta Neuropathol   137 ( 3 )   467 - 485   2019年3月

Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat

Hillebrand S, Schanda K, Nigritinou M, Tsymala I, Böhm D, PeschL P, Bauer J, Takai T, Fujihara K, Nakashima I, Misu T, Reindl M, Lassmann H, Bradl M

Acta Neuropathol   2019年3月

【視神経脊髄炎スペクトル障害（NMO-SD）】NMO-SDの疾患概念

三須　建郎、藤原　一男

脳神経内科   90 ( 1 )   1 - 6   2019年1月

Debate on the treatment of multiple sclerosis: Experience from an intractable multiple sclerosis case with rebound syndrome after fingolimod cessation

Kuroda　H, Nishiyama　S, Matsumoto Y, Misu T, Fujihara K, Aoki M

Clin Exp Nuroimmunol 10   2019年

Trial of eculizumab in aquaporin-4 positive neuromyelitis optica spectrum disorder

Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM

N Engl J Med   2019年

A randomised, placebo-controlled, double-blind trial of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: results of the N-MOmentum study

Cree B, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E

Lancet   2019年

NMO spectrum and MOG-antibody-related disseminated encephalomyelitis

Misu T, Fujihara K

Clin Exp Neuroimmunol   2019年

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations.

Jurynczyk M, Jacob A, Fujihara K, Palace J.

Pract Neurol   2018年12月

脱髄性疾患

北山通朗, 藤原一男

研修医が知っておきたい神経疾患の診断と治療   11 ( 10 )   56 - 67   2018年12月

視神経脊髄炎関連疾患と抗AQP4抗体　NMOSDの診断基準

松本勇貴, 藤原一男

Clinical Neuroscience,中枢神経系脱髄疾患-最前線抗MOG抗体の関与を考える   36 ( 11 )   1306 - 1309   2018年11月

MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antikörpertestung.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

Nervenarzt   2018年9月

虚血性心疾患によって発症した若年発症の両眼非動脈炎型虚血性視神経症の1例

小林奈美江, 小野田貴嗣, 小林健太郎, 永沼和香子, 藤原一男

臨床眼科   72 ( 9 )   1241 - 1247   2018年9月

多発性硬化症の創薬の展望

越智博文, 藤原一男

医薬ジャーナル, 神経難病と創薬   54 ( 7 )   1661 - 1667   2018年7月

神経脊髄炎　多発性硬化症との相違点

藤原一男

東京都医師会雑誌   71 ( 5 )   384 - 388   2018年6月

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

J Neuroinflammation   3 ( 15(1) )   134   2018年5月

MOG-IgG-associated optic neuritis, encephalitis, and myelitis (MONEM): lessons learned from neuromyelitis optica spectrum disorder.

dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K, Sato DK.

Front Neurol   2018年4月

Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulins.

Matsumoto Y. Norshalena S, Tsuchiya M, Kaneko C, Kubo J, Yamamoto T, Takahashi T, Fujihara K.

Mult Scler J Exp Transl Clin.   9 ( 4(1) )   2018年3月

Myelin oligodendrocyte glycoprotein immunoglobulin G‐associated disease: An overview

Fujihara K, Sato DK, Nakashima I, Takahashi T, Kaneko K, Ogawa R, Akaishi T, Matsumoto Y, Takai Y, Nishiyama S, Kuroda H, Misu T, Aoki M.

Clin Exp Neuroimmunol   9 ( Suppl.1 )   48 - 55   2018年

Area Postrema Syndrome: Frequency, Criteria and Severity in AQP4-IgG positive NMOSD.

Shosha E, Dubey D, Palace J, Nakashima I, MD, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Takai Y, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ.

Neurology   91 ( 17 )   e1642 - e1651   2018年

CSF cytokine profile in MOG-IgG+neurologic disease is similar to AQP4-IgG+NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.

Kaneko K, Sato DK, Nakashima I, Ogawa R, Akaishi T, Takai Y, Nishiyama S, Takahashi T, Misu T, Kuroda H, Tanaka S, Nomura K, Yuji Hashimoto Y, Callegaro D, Steinman L, Fujihara K, Aoki M.

J Neurol Neurosurg Psychiatry   89   927 - 936   2018年

A Case of Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder.

Asato Y, Kamitani T, Ootsuka K, Kuramochi M, Nakanishi K, Shimada T, Takahashi T, Misu T, Aoki M, FujiharaK, Kawabata Y.

Intern Med   7 ( 20 )   2981 - 2986   2018年

A nationwide epidemiological study of neuromyelitis optica in Japan.

Miyamoto K, Fujihara K, Kira J, Kuriyama N, Matsui M, Tamakoshi A, Kusunoki S.

J Neurol Neurosurg Psychiatry   89   667 - 668   2018年

Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol   17   162 - 173   2018年

Fingolimod-associated PML with mild IRIS in multiple sclerosis: a clinicopathological study.

Nishiyama S, Misu T, Shishido-Hara Y, Nakamichi K, Saijo M, Takai Y, Takei K, Yamamoto N, Kuroda H, Saito R5, Watanabe M, Tominaga T, Nakashima I, Fujihara K, Aoki M.

Neurol Neuroimmunol Neuroinflamm   5   e415   2018年

小児臨床検査のポイント2017】 自己抗体検査　臓器特異的自己抗体　神経疾患関連抗体　抗aquaporin-4(AQP4)抗体(解説/特集)

高橋利幸、藤原一男

小児内科   49   408 - 410   2017年11月

Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A comparison of the Wechsler Adult Intelligence Scale-III and the Wechsler Memory Scale Revised with the Rao Brief Repeatable Neuropsychological Battery.

Fujimori J, Nakashima I, Baba T, Meguro Y, Ogawa R, Fujihara K.

eNeurologicalSci   21 ( 9 )   3 - 7   2017年9月

【NMOとMSの最新情報】 NMO(neuromyelitis optica)の最新の診断基準(解説/特集)

松本勇貴, 藤原一男

脊椎脊髄ジャーナル   30 ( 8 )   736 - 741   2017年8月

Differential diagnosis of neuromyelitis optica spectrum disorders.

Kim SM, Kim SJ, Lee HJ, Kuroda H, Palace J, Fujihara K.

Ther Adv Neurol Disord   10 ( 7 )   265 - 289   2017年7月

Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies.

Fujimori J, Takai Y, Nakashima I, Sato DK, Takahashi T, Kaneko K, Nishiyama S, Watanabe M, Tanji H, Kobayashi M, Misu T, Aoki M, Fujihara K

J Neurol Neurosurg Psychiatry   88 ( 6 )   534 - 536   2017年6月

第1章　左眼の奥が痛くて、物が見えづらいんです(左眼痛、左視力低下)

黒田宙, 藤原一男

内科「症候から考える画像診断アトラス」   119   578 - 581   2017年4月

MOG-antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.

Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, Aoki M, Fujihara K

Neurol Neuroimmunol Neuroinflamm   4 ( 2 )   322 - 322   2017年1月

Impact of the Great East Japan Earthquake in 2011 on MS and NMOSD: a study in Sendai, Japan.

Kanamori Y, Nakashima I, Takai Y, Misu T, Kuroda H, Nishiyama S, Takahashi T, Sato S, Fujimori J, Higuchi J, Itoyama Y, Aoki M, Fujihara K

J Neurol Neurosurg Psychiatry   88   362 - 364   2017年

Practical issues and new horizons in MS, NMOSD and related disorders.

Fujihara K.

Clin Exp Neuroimmunol   8   1 - 2   2017年

Neuromyelitis optica spectrum disorders.

Akaishi T, Nakashima I, Sato DK, Takahashi T, Fujihara K.

Neuroimaging Clin N Am   27   251 - 265   2017年

Whole brain and grey matter volume of Japanese patients with multiple sclerosis.

Akaishi T, Nakashima I, Mugikura S, Aoki M, Fujihara K.

J Neuroimmunol   306   68 - 75   2017年

Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder.

Asgari N, Flanagan EP, Fujihara K, Kim HJ, Skejoe HPB, Wuerfel J, Kuroda H, Kim SH, Maillart E, Marignier R, Pittock SJ, Paul F, Weinshenker BG.

Neuro Neuroimmunol Neuroiflamm   4   e343   2017年

Hypoxia-like tissue injury and glial response contribute to Balo’s concentric lesion development.

Takai Y, Misu T, Nishiyama S, Ono H, Kuroda H, Nakashima I, Saito R, Kanamori M, Sonoda Y, Kumabe T, Mugikura S, Watanabe M, Aoki M, Fujihara K

Neurology   87 ( 19 )   2000 - 2005   2016年11月

Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD.

Zeka B, Hastermann M, Kaufmann N, Schanda K, Pende M, Misu T, Rommer P, Fujihara K, Nakashima I, Dahle C, Leutmezer F, Reindl M, Lassmann H, Bradl M

Acta Neuropathol Commun   4 ( 1 )   82 - 82   2016年8月

Pseudo-perifascicular atrophy in the healing phase of Jo-1 antisynthetase syndrome.

Tateyama M, Shibuya S, Sato H, Fujihara K, Aoki M

Neuromuscul Disord   26 ( 8 )   521 - 522   2016年8月

Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO.

Higuchi O, Nakane S, Sakai W, Maeda Y, Niino M, Takahashi T, Fukazawa T, Kikuchi S, Fujihara K,Matuo H

Neurol Neuroimmunol Neuroinflamm   3 ( 5 )   263 - 263   2016年7月

Demyelinating diseases in Asia.

Ochi H, Fujihara K

Curr Opin Neurol   29 ( 3 )   222 - 228   2016年6月

Anti-myelin Oligodendrocyte Glycoprotein Antibodies in a Patient with Recurrent Optic Neuritis Involving the Cerebral White Matter and Brainstem.

Adachi T, Yasui K, Takahashi T, Fujihara K, Watanabe Y, Nakashima K

Intern Med   55 ( 10 )   1351 - 1354   2016年5月

Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population.

Ogasawara M, Meguro A, Sakai T, Mizuki N, Takahashi T, Fujihara K, Tsuneoka H, Shikishima K

Jpn J Ophthalmol   60 ( 3 )   198 - 205   2016年5月

Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord.

Oji S, Nicolussi EM, Kaufmann N, Zeka B, Schanda K, Fujihara K, Illes Z, Dahle C, Reindl M, Lassmann H, Bradl M

PLoS One   2016年3月

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.

Nour MM, Nakashima I, Coutinho E, Woodhall M, Sousa F, Revis J, Takai Y, George J, Kitley J, Santos ME, Nour JM, Cheng F, Kuroda H, Misu T, Martins-da-Silva A, DeLuca GC, Vincent A, Palace J, Waters P, Fujihara K, Leite MI

Neurology   86 ( 1 )   79 - 87   2016年1月

Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.

Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, Hyun JW, Oliveira LM, Reindl M, Seifert-Held T, Sepulveda M, Siritho S, Waters PJ, Kurosawa K, Akaishi T, Kuroda H, Misu T, Prayoonwiwat N, Berger T, Saiz A, Kim HJ, Nomura K, Callegaro D, Fujihara K, Aoki M

J Neurol Neurosurg Psychiatry   2016年1月

Placebo-controlled study in neuromyelitis optica-Ethical and design considerations

Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E

Mult Scledr   2016年

MRI and retinal abnormalities in isolated optic neuritis with myelin-oligodendrocyte glycoprotein and aquaporin-4 antibodies

Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, Kurosawa K, Kaneko K, Kuroda H, Nishiyama S, Misu T, Nakazawa T, Fujihara K, Aoki M

Journal of neurology, neurosurgery, and psychiatry   2016年

The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients

Siritho S, Sato DK, Kaneko K, Fujihara K, Prayoonwiwat N

Mult Scler   2016年

Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica

Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, Ogino M, Yokota T, Miyamoto K, Niino M, Nomura K, Tomioka R, Tanaka M, Kawachi I, Ohashi T, Kaida KI, Matsui M, Nakatsuji Y, Ochi H, Fukaura H, Kanda T, Nagaishi A, Togo K, Mizusawa H, Murai H, Kira JI

Mult Scler   2016年

Quotient of cerebrospinal fluid/serum immunoglobulin G as a predictive factor for non-responders to intravenous methylprednisolone therapy in patients with relapsing neuromyelitis optica spectrum disorder: implication for early institution of plasmapheresis.

Oji S, Tanaka S, Kojima M, Fukaura H, Mori M, Takahashi T, Fujihara K, Nomura K

Clin Exp Neuroimmunol   7   272 - 280   2016年

The Binding Property of a Monoclonal Antibody Against the Extracellular Domains of Aquaporin-4 Directs Aquaporin-4 Toward Endocytosis.

Huang P, Takai Y, Kusano-Arai O, Ramadhanti J, Iwanari H, Miyauchi T, Sakihama T, Han JY, Aoki M, Hamakubo T, Fujihara K, Yasui M, Abe Y

Biochem Biophys Rep   7   77 - 83   2016年

Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: pathogenetic implications in neuromyelitis optica.

Nishiyama S, Misu T, Nuriya M, Takano R, Takahashi T, Nakashima I, Yasui M, Itoyama Y, Aoki M, Fujihara K

Biochem Biophys Rep   7   45 - 51   2016年

Experimental neuromyelitis optica induces a type I interferon signature in the spinal cord.

Oji S, Nicolussi E, Kaufmann N, Schanda K, Fujihara K, Illes Z, Reindl M, Lassmann H, Bradl M

PLoS ONE   11 ( 3 )   2016年

Lesion length of optic neuritis impacts visual prognosi in neuromyelitis optica.

Akaishi T, Ichiro Nakashima, Takeshita T, Mugikura S, Sato DK, Takahashi T, Nishiyama S, Kurosawa K, Misu T, Nakazawa T, Aoki M, Fujihara K

J Neuroimmunol   293   28 - 33   2016年

Different etiologies and prognoses of optic neuritis in demyelinating diseases.

Akaishi T, Nakashima I, Takeshita T, Kaneko K, Mugikura S, Sato DK, Takahashi T, Nakazawa T, Aoki M, Fujihara K

J Neuroimmnol   299   152 - 157   2016年

Serological markers associated with neuromyelitis optica spectrum disorders in South India.

Pandit L, Sato DK, Mustafa S, Takahashi T, D'Cunha A, Malli C, Sudhir A, Fujihara K

Ann Indian Acad Neurol   19 ( 4 )   505 - 509   2016年

Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications".

Passos G, Sato D, Becker J, Fujihara K

Mediators Inflamm Mediators Inflamm   2016年

High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG.

Miyazaki-Komine K, Takai Y, Huang P, Kusano-Arai O, Iwanari H, Misu T, Koda K, Mitomo K, Sakihama T, Toyama Y, Fujihara K, Hamakubo T, Yasui M, Abe Y

Br J Pharmacol.   173   103 - 114   2016年

The Binding Property of a Monoclonal Antibody Against the Extracellular Domains of Aquaporin-4 Directs Aquaporin-4 Toward Endocytosis.

Huang P, Takai Y, Kusano-Arai O, Ramadhanti J, Iwanari H, Miyauchi T, Sakihama T, Han JY, Aoki M, Hamakubo T, Fujihara K, Yasui M, Abe Y

Biochem Biophys Rep   7   77 - 83   2016年

免疫性神経疾患-病態解明と治療の最前線:NMOの発症機序

小川 諒, 藤原一男

医学のあゆみ   2015年

Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation

Tateyama M, Fujihara K, Misu T, Arai A, Kaneta T, Aoki M+L16L13:L17L13:L15

BMJ Open   2015年

Importance of QAlb, QIgG, and Reibergram in inflammatory neurological disorders with disease-specific patterns of blood-brain barrier-permeability

Akaishi T, Narikawa K, Suzuki Y, Mitsuzawa S, Tsukita K, Kuroda H, Nakashima I, Fujihara K, Aoki M

Neurology and Clinical Neuroscience   2015年

Spinal cord ring enhancement in patients with neuromyelitis optica

Yokote H, Nose Y, Ishibashi S, Kamata T, Tanaka K, Takahashi T, Fujihara K, Yokota T, Mizusawa H

Acta Neurol Scand   2015年

Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report

Amano H, Miyamoto N, Shimura H, Sato D, Fujihara K, Ueno S, Nakamura R, Ueno Y, Watanabe M, Hattori N, Urabe T

BMC Neurol   2015年

Acute callosal disconnection syndrome as an initial manifestation of neuromyelitis optica spectrum disorders

Kobayashi J, Kuroda H, Ezura M, Sugeno N, Shibui A, Takahashi T, Misu T, Fujihara K, Mori E, Aoki M

Neurology and Clinical Neuroscience   2015年

The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model

Geis C, Ritter C, Ruschil C, Weishaupt A, Gr?newald B, Stoll G, Holmoy T, Misu T, Fujihara K, Hemmer B, Stadelmann C, Bennett JL, Sommer C, Toyka KV

Experimental Neurology   2015年

Multiple Sclerosis in Japan appears to be a milder disease compared to the UK

Piccolo L, Kumar G, Nakashima I, Misu T, Kong Y, Wakerley B, Ryan S, Cavey A, Fujihara K, Palace J

Journal of Neurology   2015年

Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica

Kariya Y, Kariya Y, Saito T, Nishiyama S, Honda T, Tanaka K, Yoshida M, Fujihara K, Hashimoto Y

Biochimica et Biophysica Acta (BBA) Clinical   2015年

Novel clinical grading of delayed neurologic sequelae after carbon monoxide poisoning and factors associated with outcome

Kuroda H, Fujihara K, Kushimoto S, Aoki M

Neurotoxicology   2015年

Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies.

Hino-Fukuyo N, Kazuhiro Haginoya K, Nakashima I, Sato DK, Takahashi T, Misu T, Fujihara K, Hirose M, Kakisaka Y, Uematsu M, Kobayashi T, Shigeo Kure S

Brain Dev   2015年

Comparison of the Rao Brief Repeatable Neuropsychological Battery with Wechsler Adult Intelligence Scale-III and Wechsler Memory Scale-Revised in Japanese patients with Multiple Sclerosis

Fujimori J, Baba T, Meguro Y, Nakashima I, Mori E, Fujihara K, Aoki M

Clinical and Experimental Neuroimmunology   2015年

Depressive state and chronic fatigue in multiple sclerosis

Akaishi T, Nakashima I, Misu T, Fujihara K, Aoki M

Journal of Neurology   2015年

MRI characteristics of neuromyelitis optica spectrum disorder

Kim, HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Jens Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH

Neurology   2015年

Neuromyelitis optica and multiple sclerosis: Seeing differences through Optical Coherence Tomography

Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, Tenembaum S, Banwell B, Greenberg B, Levy M, Fujihara K, Chan KH, Kim HJ, Asgari N, Sato DK, Klawiter EC, Saiz A, Wuerfel J, Zimmermann H, Green A, Villoslada P, Paul1 F

Mult Scledr   2015年

Challenges and opportunities in designing clinical trials for neuromyelitis optica

Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree B, de Seze J, Armando Flor, Fujihara K, Greenberg BM, Higashi S, Holt W, Khan OA, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter SA, Villoslada P, Walton MK, Wasiewski W, Wingerchuk D, Yeaman M

Neurology   2015年

Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder

Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository, Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, St?ve O, Aktas O, Smith TJ, Jacob A, O'Connor KVilloslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT; and the Guthy-Jackson Charitable Foundation

JAMA Neurology   2015年

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG

Neurology   2015年

視神経脊髄炎

金子仁彦、藤原一男

臨床雑誌内科　内科疾患の診断基準・病型分類・重症度   2015年

神経・筋　多発性硬化症

金子仁彦、藤原一男

臨床雑誌内科　内科疾患の診断基準・病型分類・重症度   2015年

AQP4 in biopsied demyelinating lesions as a diagnostic clue to NMOSD and MS:Final answer ?

Fujihara K, Misu T

Neurology   2015年

Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS

Zeka B, Hastermann M, Hochmeister S, Kögl N, Kaufmann N, Schanda K, Mader S, Misu T, Rommer P, Fujihara K, Illes Z, Leutmezer F, Sato DK, Nakashima I, Reindl M, Lassmann H, Bradl M

Acta Neuropathologica   2015年

Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology

Di Pauli F, Höftberger R, Reindl M, Beer R, Rhomberg P, Schanda K, Sato D, Fujihara K, Lassmann H, Schmutzhard E, Berger T

Neurol Neuroimmunol Neuroinflamm   2015年

Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody

Kurosawa K, Misu T, Takai Y, Sato DK, Takahashi T, Abe Y, Iwanari H, Ogawa R, Nakashima I, Fujihara K, Hamakubo T, Yasui M, Aoki M

Acta Neuropathologica Commun   2015年

Anti-MOG (Myelin Oligodendrocyte Glycoprotein)-positive optic neuritis with optic disc ischemia and macular star

Moura FC, Sato DK, Rimkus CM, Apostolos-Pereira SL, de Oliveira LM, Leite CC, Fujihara K, Monteiro MLR, Callegaro D

Neuro-Ophthalmology   2015年

免疫症候群(第2版)-その他の免疫疾患を含めて-】 臓器特異的自己 免疫疾患　免疫性神経・筋疾患　免疫性中枢神経疾患　視神経脊髄炎

黒澤和大, 藤原一男

日本臨床:別冊免疫症候群I   2015年

多発性硬化症(解説/特集)

藤盛寿一, 藤原一男

精神科:特集Ⅰ　免疫と精神神経疾患   2015年

神経救急・集中治療ハンドブック

（ 範囲: 第3章　神経救急・集中管理を要する神経疾患とその管理　17 脱髄疾患）

医学書院  2017年 

多発性硬化症・視神経脊髄炎診療ガイドライン 2017

医学書院  2017年 

Dynamic diagnosisに必要な脊椎脊髄の神経症候学

（ 範囲: 視神経脊髄炎(NMO)）

三輪書店  2017年 

Dynamic diagnosisに必要な脊椎脊髄の神経症候学

（ 範囲: 多発性硬化症(MS)）

三輪書店  2017年 

Pocket Drugs 2017

（ 範囲: 多発性硬化症治療薬）

医学書院  2017年 

臨床神経内科学(改訂6版)

（ 範囲: 抗アクアポリン4抗体検査）

南山堂  2016年 

臨床神経内科学(改訂6版)

（ 範囲: 脳・脊髄脱髄疾患）

南山堂  2016年 

ポケット版　神経内科　検査・処置マニュアル

（ 範囲: アフェレシス療法）

新興医学出版社  2016年 

Pocket Drugs 2016

（ 範囲: 多発性硬化症治療薬）

医学書院  2016年 

難病辞典

（ 範囲: 多発性硬化症(MS)、視神経脊髄炎(NMO、デビック病)）

学研  2015年 

Pocket Drugs 2015

（ 範囲: 多発性硬化症治療薬）

医学書院  2015年 

Diagnostic and therapeutic dilemmas : NMOSD, MOGAD versus MS.

40th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress   2024年9月  

Real-World Experience of C5 inhibitor therapy in adult patients with AQP4-Ab+ NMOSD.

In Morning Satellite-Alexion: Istanbul MS Days IX Meeting   2024年10月  

Long term safety of Satralizumab and Japanese PMS data.

40th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress   2024年9月  

Clinical spectrum of MOG antibody-associated disease.

40th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress   2024年9月  

A case of relapsing CNS disease: MS or MOGAD ?

Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) ECHO Project   2024年8月  

Global Epidemiology of NMOSD, MOGAD & Seronegative Disease (SND).

15th Guthy-Jackson Charitable Foundation NMO Roundtable Conference   2024年8月  

NMOSD: advances and challenges.

The 25th Annual Meeting of Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)   2024年6月  

Which strategies should we employ to unveil the double negative NMOSD?

The 25th Annual Meeting of Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)   2024年6月  

PACTRIMS addresses challenges of multiple sclerosis and related disorders.

19th Asian Oceanian Congress of Neurology (AOCN 2024)   2024年5月  

Treatment of MS and NMOSD in Japan. In Therapeutic algorithms in different regions of the globe: experience and adaptations in the clinical practice of each center

Grupo Estudos Esclerose Multipla (GEEM) 2024   2024年4月  

Management of MS in Japan.

2nd Africa Mena Brain Week   2024年2月  

Epidemiology and diagnosis of NMOSD and MOGAD.

2nd Africa Mena Brain Week   2024年2月  

Immunopathology of MOGAD.

Symposium 2. MOG antibody-associated disease (MOGAD):5th Annual Congress of Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS)   2024年1月  

NMOSD: an update.

Plenary Lecture 2. 5th Annual Congress of Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS)   2024年1月  

Treatment of progressive multiple sclerosis.

European Charcot Foundation Symposium in 15th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS)  

Inebilizumab, B cells and NMOSD: lessons learned in N-Momentum study.

Mitsubishi Tanabe Symposium in 15th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) Congress  

NMOSD 2023 – an update (cell damage markers & relapse prevention.)

Special session on NMOSD and other IIDMD of the CNS, 8th Istanbul MS Days.Cesme (Turkey)  

Diagnosis of MS and NMOSD.

Teaching Course (MULTIPLE SCLEROSIS: DEMYELINATING DISEASES: FROM EPIDEMIOLOGY TO DIAGNOSIS), 26th World Congress of Neurology.  

Diagnostic considerations for MS across the world.

Scientific Session (MS AND DEMYELINATING DISEASES: WFN/MSIF JOINT SESSION - INTERNATIONAL PERSPECTIVES ON THE DIFFERENTIAL DIAGNOSIS OF MS), 26th World Congress of Neurology.  

How satralizumab changed treatment strategy of NMOSD.

Product Theater, 9th Joint ECTRIMS-ACTRIMS Meeting (MSMilan2023)  

(NMOSD: The future has come) Personalizing therapy in NMOSD.

The 2nd CUEM International Symposium "Hot topics in MS and NMOSD". Buenos Aires (Argentina)  

Immunopathology of NMOSD and MOGAD.

16th International Society of Neuroimmunology Congress.  

Case: 12 year-old girl who presented with bilateral visual impairment and subsequently had two relapses.

Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) ECHO Project, (Brazil)  

Update on the clinical use of Dimethyl Fumarate in the treatment of multiple sclerosis using a modified Delphi method.

Inter Continental Dialogue, (China)  

What are the present trends in NMOSD Research?

The 24th Annual Meeting of Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)  

Meet the expert.

The 24th Annual Meeting of Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)  

Pathophysiology of NMOSD revisited.

The 24th Annual Meeting of Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)  

When and how to treat MOGAD patients in clinical practice.

The 3rd Virtual Symposium NMOSD and MOGAD in LATAM: improving patient care  

Neural (astrocyte and others) damage markers.

In Hot Topic 2 Biomarkers in individual patients: their pathological accuracy and clinical predictive value, MOGAD Eugène Devic European Network (MEDEN) Oxford  

Neuromyelitis optica (NMO, Devic-Syndrome). Symptoms of NMOSD.

Module 2.3.3 NMO II: Charcot Multiple Sclerosis Master (Master of Science), Dresden International University (Germany) in cooperation with European Charcot Foundation  

Neuromyelitis optica (NMO, Devic syndrome). Pathogenesis of NMOSD.

Module 2.3.2 NMO I: Charcot Multiple Sclerosis Master (Master of Science), Dresden International University (Germany) in cooperation with European Charcot Foundation  

Clinical spectrum and treatment of NMOSD.

4th International Taiwanese Congress of Neurology (2023 Annual Meeting of Taiwan Neurologyical Society)  

Epidemiology of NMOSD and MOGAD.

1st African Brain Week  

An Update on Pathophysiology of NMOSD.

4th Annual Congress of Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS)  

Clinical Pearls/Red Flags: Distinguishing NMOSD and MOGAD from Presentations of MS.

Finding NEMO: NMOSD and MOGAD 101 (Western University and Canadian Federation of Neurological Sciences Review Course)  

MOG-antibody-associated disease (MOGAD).

4th Annual Congress of Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS)  

How and when to treat AQP4-IgG-positive NMOSD.

38th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)  

Pathology of MOGAD

MOG Therapeutic Roundtable  

BIR MS Medical Education 2022

BIR MS Medical Education 2022  

Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)

ECHO Project  

What comes next to double seronegative NMOSD? Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)

23rd Annual Meeting.  

PACTRIMS and research of MS and related diseases in Asia. Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)

23rd Annual Meeting.  

Geographic considerations—Asian region

Virtual meeting of International Advisory Committee on Clinical Trials in MS.  

When, how and which patient to assess AQP4-IgG and/or MOG-IgG: practical considerations.

When, how and which patient to assess AQP4-IgG and/or MOG-IgG: practical considerations.  

Istanbul MS Days VII,

Istanbul MS Days VII  

Autoantibody assay methods and their interpretation.

Pan-Asian Course for Training in MS And Neuroimmunology (PACTMAN)  

CNS Demyelination: recent advances and challenges, Therapeutic advances in NMOSD.

3rd Annual Congress of Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS).  

Case 1: A 44yo man who had aphasia 5 years after brainstem encephalitis, Case 2: A 28yo woman who had weakness and hearing impairment.

3rd Annual Congress of Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS).  

Update on the Treatment of NMO.

6th Congress of Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS)  

(Charcot Lecture) Neuromyelitis Optica: evolution of the concept and challenges.

29th Annual Meeting of the European Charcot Foundation.  

(Educational Session 16: Old and new players in the treatment of NMOSD) Treatment targets in NMOSD: a pathophysiological view.

37th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS)  

Panel Discussion: 2. Is anti MOG a disease or one of the many variants of MS?

15th Congress of International Society of Neuroimmunology (ISNI)  

(Charcot Symposium: MS, NMOSD and ANTI-MOG: similarities and differences) Lessons from experimental studies.

11th Congress of Latin American committee for Treatment and Research in Multiple Sclerosis (LACTRIMS)  

(Panel Discussion) Is anti MOG a disease or one of the many variants of MS?

15th Congress of International Society of Neuroimmunology (ISNI)  

(Main room: Symposium) Diseases associated with NMO-IgG and MOG-IgG , when to treat ?

11th Congress of Latin American committee for Treatment and Research in Multiple Sclerosis (LACTRIMS)  

(Satellite Symposium 10) The evolving landscape in NMOSD management.

37th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS)  

(Scientific Session 11: Global networks in MS) The power of global scientific collaboration.

37th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS)  

(Session 1) Personalizing Maintenance Therapy: Factors & Formula.

Guthy-Jackson Charitable Foundation Pre-ECTRIMS NMOSD Roundtable Symposium Tuesday  

(TEACHING COURSE B - MULTIPLE SCLEROSIS AND OTHER DEMYELINATING DISEASES: TREATMENT OF MS AND OTHER NEUROINFLAMMATORY DISEASES) Treating NMOSD.

25th World Congress of Neurology.  

(TEACHING COURSE A- AUTOIMMUNE NEUROLOGICAL DISORDERS HOW DO I TREAT NEUROMYELITIS OPTICA.

25th World Congress of Neurology.  

(Main Topic A: MS AND DEMYELINATING DISEASES - THE OTHER DEMYELINATING DISEASES: NMOSD AND ANTI MOG). UPDATE ON TREATMENT OF THE OTHER DEMYELINATING DISEASES.

25th World Congress of Neurology.  

(NMOSD/MOGAD Session) NMOSD and MOGAD: evolution of the clinical and pathophysiological concepts.

VIII Annual Congress of Hungarian Neuroimmunology Society  

(ECF Symposium: Update on pathogenesis and treatment of inflammatory demyelinating diseases) What is new in pathogenesis and treatment of NMOSD.

24th Annual Conference of Chinese Neurological Association.  

(Case study) A 44yo man who had aphasia 5 years after brainstem encephalitis.

Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) 2021  

(PACTRIMS Pan-Asian Course for Training in MS and Neuroimmunology (PACTMAN) Webinar Series 2)Mimickers and Differential Diagnosis of CNS Inflammatory Diseases.

PACTRIMS Pan-Asian Course for Training in MS and Neuroimmunology (PACTMAN) Webinar Series 2  

(Guthy-Jackson Charitable Foundation Symposium) Evolving Classification of NMO & Related Disorders.

8th Mexican Committee for Treatment and Research in Multiple Sclerosis (MEXCTRIMS)  

(Scientific session: Neuromyelitis Optica Spectrum Disorders – Part I) Prognostic factors in NMOSD.

Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) 2021 (22nd Annual Meeting)  

(Aluízio Marques Lecture) Lucky Science.

Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) 2021 (22nd Annual Meeting)  

(Symposium 1: SLCTRIMS-ECF, Recent advances and updates on treatment of MS and NMOSD: Neuromyelitis Optica Spectrum Disorders (NMOSD).

2nd Annual Congress of Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS).  

(Symposium 1: SLCTRIMS-ECF, Recent advances and updates on treatment of MS and NMOSD: Paediatric MOG-antibody-associated disease (MOGAD).

2nd Annual Congress of Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS).  

Biomarkers and Update on Treatment of NMOSD. Indonesia Neuromyelitis Optica Spectrum Disorders (NMOSD).

Class: A Class Program for Neurology Residents  

(NMO Symposium: Neuromyelitis spectrum disorders: Recognition to approved treatment in two decades), NMOSD) Evolution of the current concept.

14th World Congress on Controversies in Neurology (CONy)  

(NMOSD: Part 1) Pathology and Pathophysiology of NMOSD.

Virtual Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) 2020 (21st Annual Meeting)  

(CTRIMS Session) Therapy of NMOSD.

Virtual Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) 2020 (21st Annual Meeting)  

Neuromyelitis Optica Spectrum Disorders (NMOSD): pathophysiological and clinical aspects.

European Charcot Foundation Symposium (Recent developments in Diagnosis and Treatment of CNS Demyelinating Diseases) in Chinese Medical Network of Neuroinflammation (CMNN) and Annual congress of Chinese Medical Society (Neurology)  

Does early detection reduce the burden of NMOSD ?.

touchSATELLITE SYMPOSIUM (Seeing a difference in Neuromyelitis Optica Spectrum Disorder: Integrating novel strategies into care) at MSVirtual2020, (8th Joint ACTRIMS-ECTRIMS Meeting)  

(Teaching Course: Neuromyelitis optica and related syndromes: tackling the challenges) The treatment of NMOSD: a new era of choice.

MSVirtual2020 (8th Joint ACTRIMS-ECTRIMS Meeting)  

(Virtual module 1) NMOSD

Pre-ACTRIMS-ECTRIMS joint virtual meeting  

Expert Talk 2: NMOSD and MOGAD: recent developments and challenges.

AGRIM Neuroimunology Webinar Series  

(Controversies debate) There are cognitive deficits in non-brain NMOSD, NO.

European NMO Meeting 2020  

Neuromyelitis Optica, Clinical Aspects of Therapy

5th Middle-East and North African Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS)  

MOG-antibody-associated disease. From immunology to treatment

Japanese Multiple Sclerosis Society International symposium  

From Immunology to Treatment

27th Annual Meeting of the European Charcot Foundation  

Lumpers and splitters in NMOSD: Does it matter?

12th Pan-Asian Committee for Treatment and Research in Multiple Sclerosisi (PACTRIMS)  

NMO and MOG-SD

Istanbul MS Days 2019  

アクアポリン研究の最前線、病態生理の理解から新たな診断・治療法の開発まで：アクアポリン4と視神経脊髄炎

第13回 In vivp実験医学シンポジウム  

2013年及び2019年の調査による多発性硬化症における就労支援の検討

第31回日本神経免疫学会学術集会  

治療抵抗性の重症抗MOG抗体関連疾患に対するリツキシマブの使用経験

第31回日本神経免疫学会学術集会  

MS TREATMENT GUIDELINES

IS AN INTERNATIONAL CONSENSUS POSSIBLE?  

MOG-antibody-associated disease

Tiantian Neuroinfection & Neuroimmunology Forum (TNNF) 2019 Chinese Medical Network for Neuroinflammation (CMNN) 2019  

An approach to chronic inflammatory optic neuropathy (CRION)

1st Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS) Congress  

An introduction to CNS inflammatory demyelinating disorders

1st Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS) Congress  

New Diagnostic Criteria for MS, a way forward

1st Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS) Congress. Colombo (Sri Lanka)  

NMO spectrum disorders: from diagnosis to treatment

1st Sri Lankan Commitee for Treatment and Research in Multiple Sclerosis (SLCTRIMS) Congress  

（ランチョンセミナー）多発性硬化症とPML：神経感染症専門医・多発性硬化症専門医それぞれの立場から

第24回日本神経感染症学会学術集会  

Demyelinating Disease: MS, NMOSD and MOG-antibody-associated disease

AIMS Neuro Imaging 2019  

（ランチョンセミナー）NMOSDの診断における最新知見と今後の方向性

第31回日本神経免疫学会学術集会  

抗MOG抗体関連疾患急性期治療後の経時的障害度と予後の検討

第31回日本神経免疫学会学術集会  

MSフィンゴリモド導入例におけるリンパ腫合併例の、自験例および他の症例報告の比較

第31回日本神経免疫学会学術集会  

MS/NMO 2　視神経脊髄炎中枢組織障害に対するIL-6の影響に関する病理学的検討

第31回日本神経免疫学会学術集会  

MS/NMO 2　N-Momentum試験　視神経脊髄炎におけるイネビリズマブのランダム化、プラセボ対照、二重盲検試験

第31回日本神経免疫学会学術集会  

臨床ケース　神経ベーチェット病に類似した症例を呈した抗MOG抗体陽性脳炎の2例

第31回日本神経免疫学会学術集会  

急性脳炎・脳炎　NMDA型およびAMPA型抗グルタミン酸受容抗体陽性脳炎における臨床・画像・病理の比較検討

第31回日本神経免疫学会学術集会  

MS/NMO 1 Efficacy and safety of satralizumab: double-blind placebo-controlled P2 studies in NMOSD patients

第31回日本神経免疫学会学術集会  

自己免疫性脳炎　抗MOG抗体陽性患者におけるT細胞反応性に関する検討

第31回日本神経免疫学会学術集会  

Treatment of NMOSD

The 20th Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)  

Neuropathological findings of MOG-antibody-associated disease

The 20th Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)  

a possible outcome: New endpoints in clinical trials for MS: remyelination, clinical improvement and more

The 20th Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)  

Guthy-Jackson Charitable Foundation Symposium: NMOSD: epidemiology update

The 20th Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)  

Spectrum of NMO: new developments and challenges

The 5th Indian Committee for Treatment and Research in Multiple Sclerosis (ICTRIMS)  

The differential diagnosis; NMOSD, MS, and anti-MOGymposium (role of biomarkers in demyelinating diseases)

The 5th Indian Committee for Treatment and Research in Multiple Sclerosis (ICTRIMS)  

Update on NMOSD and MOG-IgG+disease

The 5th Neuroimmunology and Neurological Infections Conference (NIC) and China Neuroimmunology Congress  

Diagnosis of NMOSD

Symposium of Neuroimmunology  

Charcot Lecture: NMO/NMOSD and anti-MOG related CNS Demyelinating Diseases.

The 54th Canadian Neurological Sciences Federation Congress  

NMOSD: Burden of the disease and challenging cases

Ask The Expert  

NMO Spectrum Disorders

HCP-HCP Preceptorship  

多発性硬化症、視神経脊髄炎とMOG抗体陽性疾患

帝人ファーマ大学担当者研修2019  

視神経脊髄炎とMOG抗体陽性疾患　最近の進歩

第48回全国多発性硬化症友の会医療講演会  

再発予防投与を行わなかった抗MOG抗体陽性小児疾患における長期予後

第61回日本小児神経学会学術集会  

多発性硬化症における重症度評価にはどのような尺度を用いるべきか

第60回日本神経学会学術集会  

．補体からみた神経免疫疾患の病態解明と治療の最前線　補体阻害薬はNMOSD治療を変えることができるのか

第60回日本神経学会学術集会  

複視で発症し、脳幹とその外縁に造影効果を認めた抗MOG抗体陽性例

第60回日本神経学会学術集会  

5年間のフィンゴリモド治療中にびまん性大細胞性B細胞リンパ腫を発症した一例

第60回日本神経学会学術集会  

多発性硬化症と関連疾患：診療に役立つ治療と病態疾患のトピックス

第38回京都神経フォーラム  

The clinical spectrum and prognosis of MOG-Ab associated disease

European Committee for Treatment and Research in Multiple Sclerosisi (ECTRIMS) 7th Focused Workshop: MOG-antibody-associated Disease  

視神経脊髄炎：疾患概念の変遷と自己免疫性アストロサイトパチーの病態

千里ライフサイエンス新適塾「難病への挑戦」第37回会合  

Session V – Long term observation of diseases at the border of MS and of pediatric MS: NMO Spectrum Disorders.

26th Annual Meeting of European Charcot Foundation.  

Plenary Session 2: Demyelinating Disorders, Diagnostic approach in CNS Demyelinating Diseases.

16th Asian Oceanian Congress of Neurology.  

Symposium-3: Comprehensive Management of MS and NMOSD in Asia-Pacific Regions. L-13 The Approach to the Management of Indeterminate MS/NMOSD.

11th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTIRMS)  

Toward approved NMOSD therapeutics: clinical perspectives.

Guthy-Jackson Charitable Foundation NMO Symposium (Global Partnerships for Cures)  

NMO Spectrum Disorders: an Update.

3rd Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS)  

Teaching Course 23: NMOSD Current concept and clinical management: MOG-antibody disease update and differentiation from MS and AQP4-antibody positive disease.

34th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS)  

Was anything left aside in the 2017 McDonald criteria for the diagnosis of MS?

19th Annual Congress of Brazilian Committee for Treatment and Research in multiple Sclerosis (BCTRIMS)  

Predominantly spinal MS versus seronegative NMOSD: diagnostic issues.

19th Annual Congress of Brazilian Committee for Treatment and Research in multiple Sclerosis (BCTRIMS)  

Geoepidemiology: World atlas of NMO. NMO state of the union, building on success: the next decade of NMO.

10th Annual International NMO Roundtable Conference  

Diagnostic criteria of MS and NMO.

XXI Symposium Neuroradiogicum (SNR 2018)  

Update on pathogenesis of NMOSD

Istanbul MS Days 2017  

そうだ！専門医に聞いてみよう 多発性硬化症/視神経脊髄炎

いばらき難病大学2017  

Symptomatic treatment in MS, NMOSD

European Charcot Foundation Symposium in The 10th Pan-Asian Committee for Teratment and Resarch in Multiple Sclerosis (PACTRIMS)  

マラソンレクチャー3, NMO Spectrum Disorders：これからの治療

第35回日本神経治療学会総会  

Update on pathogenesis of NMOSD

The 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis 2017)  

Pathogenesis of NMOSD. In Main topic M02B: MS AND OTHER INFLAMMATORY DISEASES: Immunopathology and Pathogenesis of MS and NMOSD

The 23rd World Congress of Neurology  

Rheurmatology and NMO overlap.

The 23rd World Congress of Neurology  

ミニシンポジウム: 補体関連疾患の新展開～補体の関与と新規治療戦略の可能性～, 視神経脊髄炎(NMO)における補体の病態及び治療的意義

第54回日本補体学会学術集会  

Intermediate forms between MS and seronegative NMOSD, How to solve this diagnostic puzzle ?

The 18th Meeting of Brazilian Committee for Treatment and Resarch in Multiple Sclerosis (BCTRIMS)  

Diagnostic criteria of MS: new insights and challenges

The 18th Meeting of Brazilian Committee for Treatment and Resarch in Multiple Sclerosis (BCTRIMS)  

Is NMO a disease or syndrome with different etiologies ?

The 18th Meeting of Brazilian Committee for Treatment and Resarch in Multiple Sclerosis (BCTRIMS)  

多発性硬化症/視神経脊髄炎の治療と日常生活について

H29年度福島県難病医療・就労支援セミナー  

NMOSD: an update

The 3rd Indian Committee for Treatment and Resarch in Multiple Sclerosis (ICTRIMS)  

MOG-IgG-associated neurologic disease

The 3rd Indian Committee for Treatment and Resarch in Multiple Sclerosis (ICTRIMS)  

MOG-IgG-associated Disease

The 4th MS Summer College in Kobe  

Evolution of disgnostic criteria and its impact on disease management.

UCB APAC MS Summit 2017  

MSとNMOを理解しよう

第4回北海道MS・NMO医療フォーラム  

MOG抗体陽性神経疾患のお話し

第46回全国多発性硬化症友の会医療講演会  

Overview of clinical signs and symptoms of spinal cord pathology in MS and NMOSD: gait, pain, bladder/bowel, sexual function

International Conference on Spinal Cord Involvement and imaging in MS and NMOSD  

MS、NMOと関連疾患：鑑別疾患とマネージメントに必要な基礎知識

埼玉MS・NMO研究会2017  

Specifying diagnosis. AQP4-reactive and MOG-reactive NMOSD are mutually exclusive diesases.

9th Annual International Roundtable Conference on NMO (Guthy-Jackson Charitable Foundation)  

The world of MS, MS in the world

The 4th international Porto Congress of Multiple Sclerosis  

多発性硬化症治療の戦略とリスクマネージメント. 多発性硬化症治療の戦略とリスクマネージメント

Kitakanto Neuroscience Forum  

多発性硬化症のマネージメントと鑑別診断

AD/PD/MS Forum 2017 Meet the Expert in Hyogo  

多発性硬化症と視神経脊髄炎に関連したバイオマーカー：AQP4抗体とMOG抗体

第56回日本臨床化学会年次学術集会シンポジウム  

私のNMOSD, MS研究史

埼玉医科大学神経内科萬象会  

Using MRI to diagnose MS and related disorders Case examples of other MS mimics.

The 9th Annual Congress of Pan-Asian Committee on Treatment and Research in Multiple Sclerosis (PACTRIMS)  

Progressive MS in Asia.

The 9th Annual Congress of Pan-Asian Committee on Treatment and Research in Multiple Sclerosis (PACTRIMS)  

Autoimmune neurologic disorders, Aquaporin 4 antibody in neuromyelitis optica spectrum disorders.

The 13th International Wrokshop on Autoantibodies and Autoimmunity  

多発性硬化症の鑑別診断と治療の選択

第28回日本神経免疫学会学術集会ランチョンセミナー  

そこが知りたい！MS治療の最先端

茨城県難病団体連絡協議会医療講演会・相談会・交流会  

New trial designs and treatment approach for NMO.

32th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS)  

Neuromyelitis Optica Spectrum Disorders. Pathomechanisms of AQP4-Ig+, MOG-IgG+ and Seronegative Diseases.

32th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS)  

MS (PACTRIMS) 1 - Classic Multiple Sclerosis. Classic MS: Update on Pathogenesis.

15th Asian and Oceanian Congress of Neurology (AOCN)  

Multiple Sclerosis (PACTRIMS) 2-MS Related Disorder. Implications of The New Diagnostic Criteria of NMOSD

15th Asian and Oceanian Congress of Neurology (AOCN)  

The Diagnostic Challenge of Multiple Sclerosis.

UCB APAC MS Summit  

MSの鑑別診断と薬剤選択について

日本神経学会第105回近畿地方会ランチョンセミナー  

Optic Neuritis: Pathology and Differential Diagnosis.

17th Annual Meeting of Brazilian Committee on Treatment and Research in Multiple Sclerosis (BCTRIMS),  

Epidemiology of Multiple Sclerosis in Asia: An Overview (PACTRIMS).

17th Annual Meeting of Brazilian Committee on Treatment and Research in Multiple Sclerosis (BCTRIMS)  

Critical Comparative Analysis of the Revised 2006 Criteria and the International Consensus Criteria (2015) for Diagnosis of NMOSD.

17th Annual Meeting of Brazilian Committee on Treatment and Research in Multiple Sclerosis (BCTRIMS)  

NMO/NMO Spectrum Diseases (in honor of Eugene Devic), IX. International consensus diagnostic criteria of NMOSD.

Clinical Neuroimmunology Symposium  

Neuromyelitis optica spectrum disorders (NMOSD) and MOG-IgG.

The 2nd Chinese International Summit Meeting of Neuroinfection, Immunity and Cerebrovascular Diseases  

視神経脊髄炎の新しい診断基準

第57回日本神経学会学術大会教育コース  

多発性硬化症と視神経脊髄炎の診断と治療

日本医師会医学講座 (ラジオNIKKEI)  

NMOと抗MOG抗体

多発性硬化症講演会 in Kansai  

多発性硬化症と視神経脊髄炎の診断と治療

第97回日本神経学会東北地方会ランチョンセミナー  

多発性硬化症の早期診断と治療

第3回フィンゴリモドフォーラム  

MSとNMOの鑑別ポイント

イムセラWEBセミナー  

多発性硬化症と関連疾患：診療に役立つ治療と病態

第2回四国MSセミナー  

How to diagnose and treat indistinguishable early cases of inflammatory CNS diseases in Asians, New Diagnostic Criteria of NMOSD

The 8th Annual Meeting of Pan-Asian Committee for Treatmetn and Research in Multiple Sclerosis (PACTRIMS)  

Focus on NMO Spectrum Disorders

Top Seminars in Multiple Sclerosis 2015  

Neuroimmunology and Multiple Sclerosis, Update in NMO

The 22nd World Congress of Neurology  

Multiple Sclerosis and Other Demyelinating Diseases, Our Current Understanding of NMO and its Spectrum Disorders

The 22nd World Congress of Neurology  

Is there an "Eatern Type of MS”

Istanbul MS Days 2015  

Neuw insights into the Molecular Pathogenesis of NMO Spectrum Disorders

European Charcot Foudantion Symposium in The 8th Annual Meeting of Pan-Asian Committee for Treatmetn and Research in Multiple Sclerosis (PACTRIMS)  

Prevalence and Phenotypes of Demyelinating Diseases Outside Europe and NA: Asia

The 31st Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)  

A young lady with severe myasthenia and emaciation

The 16th Annual Conference of Indian Academy of Neurology  

The Concept of Neuromyelitis Optica Spectrum Disorders: Its Evolution and Lessons

The 16th Annual Conference of Indian Academy of Neurology  

Neuromyelitis Optica Spectrum Disorders: Pathophysiology of NMOSD

The 31st Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)  

Evolving concept of NMO Spectrum Disorders: what can we learn ?

The 1st Chinese International Summit Meetin g of Neurimmunology and Neuroinfections  

NMO and its Spectrum Disorders: an international perspective

The 67th Annual Meeting of American Academy of Neurology  

神経免疫疾患のエビデンスによる診断基準・重症度分類・ガイドラインの妥当性と患者QOLの検証

2019年4月 - 2020年3月

松井　真、荻野　美恵子, 梶　龍兒, 河内　泉, 神田　隆, 吉良　潤一, 楠　進, 栗山　長門, 桑原　聡, 酒井　康成, 清水　潤, 清水　優子, 園生　雅弘, 祖父江　元, 田原　将行, 中辻　裕司, 中原　仁, 中村　幸志, 中村　好一, 新野　正明, 野村　恭一, 藤原　一男, 松尾　秀徳, 村井　弘之, 本村　政勝, 山村　隆, 横田　隆徳, 吉川　弘明, 渡邊　修

神経免疫疾患のエビデンスによる診断基準・重症度分類・ガイドラインの妥当性と患者QOLの検証

2018年4月 - 2019年3月

松井　真、荻野　美恵子, 梶　龍兒, 河内　泉, 神田　隆, 吉良　潤一, 楠　進, 栗山　長門, 桑原　聡, 酒井　康成, 清水　潤, 清水　優子, 園生　雅弘, 祖父江　元, 田原　将行, 中辻　裕司, 中原　仁, 中村　幸志, 中村　好一, 新野　正明, 野村　恭一, 藤原　一男, 松尾　秀徳, 村井　弘之, 本村　政勝, 山村　隆, 横田　隆徳, 吉川　弘明, 渡邊　修

ミエリンオリゴデンドロサイト糖タンパク（MOG）抗体関連神経疾患の臨床・病態解析

2018年4月 - 2019年3月

ミエリンオリゴデンドロサイト糖タンパク（MOG）抗体関連神経疾患の臨床・病態解析

2017年4月 - 2018年3月

神経免疫疾患のエビデンスによる診断基準・重症度分類・ガイドラインの妥当性と患者QOLの検証

2017年4月 - 2018年3月

松井　真、荻野　美恵子, 梶　龍兒, 河内　泉, 神田　隆, 吉良　潤一, 楠　進, 栗山　長門, 桑原　聡, 酒井　康成, 清水　潤, 清水　優子, 鈴木　則宏, 園生　雅弘, 祖父江　元, 田原　将行, 中辻　裕司, 中村　幸志, 中村　好一, 新野　正明, 野村　恭一, 藤原　一男, 松尾　秀徳, 村井　弘之, 本村　政勝, 山野　嘉久, 山村　隆, 横田　隆徳, 吉川　弘明, 渡邊　修

エビデンスに基づいた神経免疫疾患の早期診断基準・重症度分類・治療アルゴリズムの確立

2014年4月 - 2017年3月

松井真、池田修一　荻野美恵子　梶龍兒　神田隆　吉良潤一　楠進　久保田龍二　桑原聡　清水潤　清水優子　鈴木則宏　園生雅弘　祖父江元　竹内英之　田中正美　中辻裕司　新野正明　河内泉　野村恭一　酒井康成　藤原一男　松尾秀徳　横田隆徳　木村政勝　山村隆　吉川弘明　渡邊修

HAMの革新的な医薬品等の開発促進に関する研究

2014年4月 - 2017年3月

山野嘉久、長谷川泰弘　新野正明　藤原一男　中川正法　竹之内徳博　永井将弘　吉良潤一　中村龍文　髙嶋博　渡嘉敷崇　米澤久司　坪井義夫　髙田礼子　齊藤峰輝　外丸詩野　植田幸嗣　松田文彦　井上永介

非典型的多発性硬化症の臨床・病態解析

2014年4月 - 2016年3月